Patent · US Active

Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof

US10709718B2 · kind B2 · utility

0Cited by

9References

11Claims

0Family size

Assignee

Metabasis Therapeutics, Inc. · US

Inventors

K. Raja Reddy · San Diego, US
Jeff Stebbins · San Diego, US
Serge Boyer · San Diego, US
Mark D. Erion · Del Mar, US
Scott Hecker · Del Mar, US
Nicholas Brian Raffaele · San Diego, US
Brett C. Bookser · San Diego, US
Venkat Reddy Mali · Cupertino, US

Key dates

Filing date	Jul 2, 2018
Grant date	Jul 14, 2020
Priority date	—
Expiry date	Jul 2, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07F9/65742
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention pertains to the use of fused bicycle heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.